Neuphoria Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Neuphoria Therapeutics Inc.'s yearly results (2022–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 96% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.1 times its market value (net cash). Higher than 89% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 547% in 3 years; of every extra $100 of sales, $153 became extra profit. Higher than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
$153Sales grew 547% in 3 years; of every extra $100 of sales, $153 became extra profit.
Higher than 85% of Healthcare companies in United States.
Asset Productivity Ratio
+547% / -36%In 3 years sales changed by +547% while total assets changed by -36%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-359.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 96% of Healthcare companies in United States.
Cash Cushion Ratio
1.1× cashCash, after subtracting all debt, is 1.1 times its market value (net cash).
Higher than 89% of Healthcare companies in United States.
Tangible Assets Ratio
73%Of every $100 the company owns, $73 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 59% of Healthcare companies in United States.
Tangible Net Worth Ratio
69%Of every $100 of net worth, $69 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 56% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Neuphoria Therapeutics Inc. made a loss over the last year. Neuphoria Therapeutics Inc. owes $0.14 for every $1 it owns.
Compared with Healthcare companies in United States · latest annual results Jun 2026.
P/E ratio
LossNeuphoria Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.77The share price is 0.77 times Neuphoria Therapeutics Inc.'s book value per share, lower than 85% of Healthcare companies in United States.
Market cap
$19 MThe total market value of all of Neuphoria Therapeutics Inc.'s shares at today's price (share price × number of shares), smaller than 82% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$25 MWhat Neuphoria Therapeutics Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.55Net worth divided by the number of shares. The share price of $3.48 is 0.8 times this, which is the P/B above.
Return on equity (ROE)
-61.7%Neuphoria Therapeutics Inc. lost 61.7% of its shareholders' money over the last year, lower than 58% of Healthcare companies in United States.
Owes vs Owns
0.14×Neuphoria Therapeutics Inc. owes $0.14 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Dividend yield
NoneNeuphoria Therapeutics Inc. does not currently pay a dividend.
Profit margin
-1145.7%Neuphoria Therapeutics Inc. lost $1146 for every $100 of revenue.
Cash vs debt
Net cashNeuphoria Therapeutics Inc. held $20 M more cash than debt (net cash) at Jun 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Neuphoria Therapeutics Inc.: $19 M ÷ $25 M (30 Jun 2026) = 0.8.
What is Neuphoria Therapeutics Inc.'s return on equity?
Neuphoria Therapeutics Inc. lost 61.7% of its shareholders' money over the last year, lower than 58% of Healthcare companies in United States.
How much does Neuphoria Therapeutics Inc. owe compared with what it owns?
Neuphoria Therapeutics Inc. owes $0.14 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Does Neuphoria Therapeutics Inc. pay a dividend?
No. Neuphoria Therapeutics Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.